

CIRM Funded Clinical Trials

A Phase 3 Study Comparing the Utility of Human Acellular Vessels to Arteriovenous Fistula in Subjects with End-Stage Renal Disease (California Sites)

Disease Area:	Kidney Failure
Investigator:	Jeffrey Lawson
Institution:	Humacyte, Inc.
CIRM Grant:	CLIN2-09688
Award Value:	\$14,082,865
Trial Sponsor:	Humacyte, Inc.
Trial Stage:	Phase 3
Trial Status:	Recruiting
Targeted Enrollment:	240
ClinicalTrials.gov ID:	NCT03183245



Jeffrey Lawson

Design:

Humacyte is using donor cells to create an acellular bioengineered vessel needed by people undergoing hemodialysis, the most common form of dialysis. In dialysis, a person is connected to a machine that removes waste from their blood. The bioengineered vessel is implanted in the arm and used to carry the patient's blood to and from their body during dialysis. Over time the patient's own stem cells start to populate this vein, in effect making it part of the patient's own body. Humacyte is comparing the performance of its acellular bioengineered vessel with the current standard of dialysis treatment for kidney disease patients to determine if the bioengineered vessel is superior in remaining open for longer periods of time and with lower incidence of interventions due to blood clots and infections.

Updates:

Launching.

News Releases:

Humacyte Receives \$14.1 M Award from California Institute for Regenerative Medicine to Expand Clinical Applications of HUMACYL

[Contact Trial Sponsor](#)